‌ 

With Halloween behind us, the most wonderful time of year is almost here, flu season! The COVID pandemic set a new precedent for how we treat public health in the United States. People came together to slow the spread and help save as many lives as possible. With the release of the vaccine more and more are getting vaccinated every day allowing the pandemic to come to an end all the sooner.

Despite this wave of concern with public health and a desire to get vaccinated with the COVID vaccine, when it comes to the flu vaccine it is almost like nothing has changed at all. During the 2020-2021 flu season the CDC estimated that only 50 to 55% of adults in the U.S. got the influenza vaccine.[1] While this number is up from 48% vaccination rate during the 2019-2020 flu season [1] it is still abysmally low.

What many people do not know is that the flu vaccine actually works in a very similar manner to the COVID Vaccine. It takes about 2 weeks to be effective, it is not 100% effective and the possibility of getting sick still remains, but even if you do you get sick the symptoms will be far less intense and the chance of getting hospitalized is greatly reduced thanks to the vaccine, and finally, the flu vaccine can be lifesaving to high-risk individuals.[2] Again, despite these similarities, people are much less eager to get the flu vaccine than the COVID vaccine.

Perhaps it is due to the fact that the flu has a lower mortality rate than COVID. It is important to understand that, while it is lower, it is not 0. The flu can and does kill people, especially high-risk individuals like the elderly. It can be easy to forget this sometimes due to how common the flu is in our lives. Just as we care to help protect others against COVID we should care to help protect others against the flu.

The flu vaccine has to be approved by the FDA before it is made available on the market, just as with any other biologic. Market approval is an important part of production, EMMA International can help get products approved by the FDA no matter what pathway it needs. From pharmaceuticals to medical devices to biologics, EMMA International can products approved and on the market, give us a call at 248-987-4497 or email info@emmainternational.com to get in touch with our team of experts today.


[1] CDC (October 2021) 2020-21 Flu Season Summary, Retrieved 11/01/2021 from https://www.cdc.gov/flu/season/faq-flu-season-2020-2021.htm

[2] CDC (October 2021) Key Facts About Seasonal Flu Vaccine, Retrieved 11/01/2021 from https://www.cdc.gov/flu/prevent/keyfacts.htm

Gabe Kadoo

Gabe Kadoo

Mr. Kadoo is a Quality Engineer at EMMA International. He has experience in statistical analysis, performance improvement, quality assurance, and value stream mapping in the clinical setting. Mr. Kadoo also has experience as a clinical researcher and medical technologist. Mr. Kadoo holds a Bachelor of Science in Biology and a Master of Public Administration with a concentration in Healthcare Administration. He is also a Six Sigma Green Belt.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This